Dongsheng enters agreement to acquire micro-emulsion alprostadil injection from Wan'Te

Dongsheng Pharmaceutical International Co., Ltd. (the "Company") (OTC Bulletin Board: DNGH.OB) announced today that it has entered into an agreement with Shanghai Wan'Te Pharmaceutical Co., Ltd. ("Wan'Te") to acquire the intellectual property, exclusive sales and manufacturing rights of micro-emulsion alprostadil injection from Wan'Te for total proceeds of RMB10 million, of which RMB5 million will be paid in cash and RMB5 million will be paid in shares of the Company's common stock. However, if the trading price of the Company's common stock is less than $1.50 per share on the date on which the RMB5 million of common stock is to be issued, Wan'Te shall have the right, but not the obligation, to require the Company to pay to it RMB5 million in cash in lieu of such shares of common stock.

Micro-Emulsion Alprostadil Injection

Micro-Emulsion Alprostadil Injection is ranked as the No. 2 cardiovascular disease treatment measured by Chinese hospital usage, and it has experienced a growth rate of 17% per year (China Pharmaceutical News, 2010). According to the Development Research Centre of the State Council of China, the direct medical cost of cardiovascular disease in China has reached 130 billion RMB per year since 2007 (DRCnet, 2007).

Another Important Top Line Growth Engine

The Company targets launching sales of micro-emulsion alprostadil injection in March 2011. Mr. Zhu XiaoDong, CEO of Dongsheng, stated, "With full control of the technological, sales and manufacturing rights, leveraged with the Company's extensive sales network within China, alprostadil represents an exciting opportunity for Dongsheng to diversify its revenue sources."